NCT07326566 2026-03-19
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
Black Diamond Therapeutics, Inc.
Inmune Bio, Inc.
Stemline Therapeutics, Inc.
Eisai Inc.